ZimVie Announces the Recent Launch of Biotivity™ A/C Plus Membrane
10 Octubre 2023 - 7:30AM
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the
dental and spine markets, today announced the recent launch of the
Biotivity™ A/C Plus Membrane, a growth factor rich membrane used
for site coverage and protection from the oral environment in a
variety of dental applications. The membrane is now available in
the United States.
Dental bone grafting procedures, in conjunction with protective
barrier membranes, are used to repair or reconstruct the jaw and to
provide a foundation for dental implant placement. This launch
broadens ZimVie’s presence in the dental biomaterials market,
expanding into the large growth factor segment. ZimVie’s Biotivity
A/C Plus Membrane is a barrier membrane containing a variety of
growth factors, cytokines, chemokines, and hyaluronic acid shown to
facilitate wound healing.1-3
“We remain focused on bringing new products to market to meet
customer needs and ensure their teams have the best solutions at
their disposal,” said Indraneel Kanaglekar, SVP and President of
ZimVie Dental. “Biotivity’s triple-layer structure is thicker than
conventional A/C membranes and may contribute to enhanced
conformability and growth factor content.”1, 2, 4For more
information on ZimVie's Dental implants, suite of connected
solutions, and continuing education, please visit
www.zimvie.com.
About Biotivity™ A/C Plus MembraneBiotivity™
A/C Plus Membrane is a growth factor-charged membrane derived from
human placental tissue. Consisting of the amnion, intermediate, and
chorion layers, Biotivity A/C Plus is minimally manipulated using
proprietary processing that preserves natural mechanical
properties, elasticity, growth factors, cytokines, and other
biological enhancers.5, 6 The product has been sterilized using the
Excellion® Process, and terminally sterilized with Electron-Beam
irradiation. Unlike other A/C membranes available on the market
Biotivity A/C Plus is not treated with antibiotics during the
processing.5, 7
About ZimVieZimVie is a global life sciences
leader in the dental and spine markets that develops, manufactures,
and delivers a comprehensive portfolio of products and solutions
designed to treat a wide range of spine pathologies and support
dental tooth replacement and restoration procedures. The company
was founded in March 2022 as an independent, publicly traded
spin-off of the Dental and Spine business units of Zimmer Biomet to
breathe new life, dedicated energy, and strategic focus to its
portfolio of trusted brands and products. From its headquarters in
Westminster, Colorado, and additional facilities around the globe,
the company serves customers in over 70 countries worldwide with a
robust offering of dental and spine solutions, including
differentiated product platforms supported by extensive clinical
evidence. For more information about ZimVie, please visit us at
www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or
Instagram.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, statements concerning
ZimVie’s expectations, plans, prospects, and product and service
offerings, including new product launches and potential clinical
successes. Such statements are based upon the current beliefs,
expectations, and assumptions of management and are subject to
significant risks, uncertainties, and changes in circumstances that
could cause actual outcomes and results to differ materially from
the forward-looking statements. For a list and description of some
of such risks and uncertainties, see ZimVie’s periodic reports
filed with the U.S. Securities and Exchange Commission (SEC). These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in ZimVie’s filings with the SEC. Forward-looking statements speak
only as of the date they are made, and ZimVie disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise. Readers of this press release are cautioned not to
rely on these forward-looking statements, since there can be no
assurance that these forward-looking statements will prove to be
accurate. This cautionary note is applicable to all forward-looking
statements contained in this press release.
Media Contact
Information:ZimVieLaura Driscoll •
Laura.Driscoll@ZimVie.com(774)
284-1606ZimVieAllison Johnson •
Allison.Johnson@ZimVie.com(774) 266-8046
Investor Contact Information:
Gilmartin Group LLCMarissa Bych •
Marissa@gilmartinir.com
References:1. Malak T.M. et al. Placenta (1993) 14:385-406.2.
Roy A., Griffiths S. J Tissue Eng Regen Med (2020) 14:1126-1135.3.
Bryant-Greenwood G.D. Placenta (1998) 19:1-11.4. Hieber A.D. et al.
Placenta (1997) 18:301-312.5. Data on file with manufacturer.6.
Koizumi N. et al. Curr Eye Res (2000) 20:173-177.7. Biotivity
A/C Plus Membrane IFU Rev. 03.
ZimVie (NASDAQ:ZIMV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ZimVie (NASDAQ:ZIMV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024